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Clinical case 
• A 73 year-old man presents with a RUL nodule since 2010, 
when he first presented with a cough. 
 
• PMHx: COPD, peripheral vascular disease, obesity (BMI=30.4) 
 
• Smoking history: Former smoker, 1 pack per day for 40 years, 
quit 13 years ago 
 
• PFTs: Mild obstruction (FEV1= 1.9 L, 66% predicted) 
September 2010 
8mm mixed partly ground glass/ 
partly solid nodule 
July 2014 
Increase in solid component to 
7mm, with peripheral ground glass 
component now measuring 1.3cm 
CT chest 
FNA 
July 2014 
 
Non-small cell 
carcinoma, favor 
adenocarcinoma 
 
CK7 positive 
CK20 negative 
TTF-1 positive 
 
PET-CT 
July 2014 
 
Minimally FDG-
avid (SUVmax 1.5) 
1.8cm RUL opacity 
VATS RUL wedge resection and mediastinal lymph 
node dissection 
Lepidic predominant adenocarcinoma (LPA) 
Lung adenocarcinoma: 
Invasion and metastasis 
Lung cancer is a heterogeneous disease 
*EGFR 
 KRAS 
 EML4/ALK 
* 
 
LPA 
 
AIS 
Tumor invasion and metastasis 
Initial step for 
metastasis: 
• Loss of adhesion, 
mobility, basement 
membrane 
degradation 
 
 
Subsequent steps: 
• Intravasation into 
circulation, 
extravasation, and 
angiogenesis at 
target site 
Fidler, Nature Rev Cancer, 2003 
Adenocarcinoma subtype is defined by degree of 
tumor invasion 
• Lung adenocarcinoma histologic 
subtypes are associated with 
tumor invasion and have 
characteristic radiologic 
correlates. 
 
• The degree of tumor invasion on 
histologic examination predicts 
clinical outcomes. 
Travis, J Thoracic Onc, 2011; Naidich, Radiology, 2013 
Adenocarcinoma 
in situ 
Invasive 
adenocarcinoma 
Extent of invasion is independently associated with 
survival in stage I, II, IIIA  adenocarcinoma (n=183) 
 
Survival (days) 
Borczuk, Powell, Am J Surg Pathol, 2009 
Category Median survival 
BAC Not reached 
Microinvasive 
(≤ 5mm) 
Not reached 
Mixed Subtype 2421 days 
Pure Invasive 1980 days 
Lung adenocarcinoma progression is associated with 
differentially expressed genes 
Normal AAH AIS/MIA 
Invasive 
AC 
      IAC      AIS 
Proliferation Invasion Metastasis 
Borczuk, Powell, AJRCCM, 2005; Borczuk, Powell, Cancer Res, 2011  
Mediators of lung adenocarcinoma invasion in TGFβRII–
deficient tumors 
X 
Borczuk, Powell, PATS, 2009 
LOX family genes and CCL5 are differentially 
expressed in invasive lung adenocarcinoma 
Borczuk, Powell, AJRCCM, 2005 
CCL5/RANTES and LOX  and LOXL2 are important mediators of 
lung adenocarcinoma invasion in TGFβRII–deficient tumors 
X 
CCL5/RANTES; 
LOX and LOXL2 
Borczuk, Powell, PATS, 2009 
CCR5/RANTES expression in lung adenocarcinoma is 
associated with invasion and clinical outcome 
Borczuk, Powell, Oncogene, 2008 
CCR5/RANTES expression in lung adenocarcinoma is 
associated with invasion and clinical outcome 
Borczuk, Powell, Oncogene, 2008 
Lysyl oxidase (LOX) acts on the ECM to facilitate 
fibrosis, tumor cell invasion, and metastasis 
Barker, Nature Rev Cancer, 2012 
Wilgus, Powell, Cancer, 2011 
The LOX family of proteins has been implicated as 
both tumor suppressors and metastasis promoters   
• Lysyl oxidase (LOX) and LOXL2 are important for lung and breast 
tumor invasion. Expression distinguishes pre-invasive from 
invasive histology and is associated with poor survival in lung 
adenocarcinoma. 
Wilgus, Powell, Cancer, 2011; Barker, Nature Rev Cancer, 2012 
Barker, Nature Reviews Cancer, 2012 
Early Stage Lung Cancer: 
Biomarker discovery, validation, 
and new applications 
Hypothesis 
• Gap: There is a need for validated biomarkers in pre-resection 
specimens that predict tumor invasion and metastasis. 
 
• Cellular expression of LOX and LOXL2 in pre-resection 
cytologic specimens predicts lung adenocarcinoma 
invasiveness. 
 
• Objective:  To examine the association of LOX and LOXL2 
expression in fine needle aspirate (FNA) cytology specimens 
with extent of invasion in paired, surgically resected lung 
adenocarcinoma specimens. 
Methodology 
• LOX and LOXL2 gene expression was performed by quantitative polymerase 
chain reaction (qPCR) of RNA extracted from surgically resected formalin 
fixed and paraffin embedded (FFPE) tumors and using Taqman probes. 
 
• Immunohistochemistry (IHC) /Immunocytochemistry (ICC) for LOX and 
LOXL2 expression was performed on FFPE cytologic cell blocks from FNAs 
and paired, surgically resected FFPE tumors. 
1° antibody Tissue 
Cytology 
cell block 
Source 
Anti-LOX 1:3000 1:3000 Abcam 
Anti-LOXL2 1:1000 1:1000 
Santa Cruz 
Biotechnology 
• Immunostaining in tumor 
cell cytoplasm was scored as 
negative (0) or positive on a 
scale of 1 (faint) to 3 
(strong). In positive cases, an 
assessment of percent 
staining within tumors was 
performed. 
Patient and tumor demographics 
Demographics Tumors (31) 
Age, mean ± SD, y 70 ± 9 
Male, n 12 (38%) 
Tumor size, mean ± SD, cm 1.7 ± 1.1 
Pathologic stage, n 
IA 28 (91%) 
IB 2 (6%) 
2A 1 (3%) 
Adenocarcinoma subtype, n 
Adenocarcinoma in situ (AIS) 3 (10%) 
Minimally invasive adenocarcinoma (MIA) 9 (29%) 
Lepidic predominant adenocarcinoma (LPA) 4 (13%) 
Invasive, acinar predominant 9 (29%) 
Invasive, papillary predominant 4 (13%) 
Invasive, solid predominant 2 (6%) 
Molecular markers, n 
EGFR 4 (13%) 
KRAS 4 (13%) 
ALK gene rearrangement 1 (3%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LOX and LOXL2 expression is higher in resected 
invasive lung adenocarcinoma compared with 
noninvasive tumors 
LOX LOXL2 
Minimally invasive 
adenocarcinoma 
Invasive adenocarcinoma,  
papillary predominant 
Surgically 
resected 
tumor 
Cytologic 
cell block 
from FNA 
LOX expression in lung adenocarcinoma 
Minimally invasive 
adenocarcinoma 
Invasive adenocarcinoma,  
papillary predominant 
200x 100x 
40x 40x 
The frequency of LOXL2 expression is reduced in 
pre-invasive resected adenocarcinoma 
Cytoplasmic staining 
positive* 
AIS MIA LPA 
Invasive 
non-solid 
Invasive 
solid 
LOX 
Surgical specimens, 
n= 19/31 
1/3 (33%) 7/9 (78%) 2/4 (50%) 
7/10 
(70%) 
2/5 (40%) 
Cytologic specimens,  
n= 17/18 
No 
specimens 
6/6 
(100%) 
0/1 (0%) 
6/6 
(100%) 
5/5 
(100%) 
LOXL2 
Surgical specimens, 
n= 25/31 
2/3 (67%) 7/9 (78%) 
4/4 
(100%) 
10/10 
(100%) 
2/5 (40%) 
Cytologic specimens,  
n= 20/20 
No 
specimens 
7/7 
(100%) 
1/1 
(100%) 
7/7 
(100%) 
5/5 
(100%) 
*LOX and LOXL2 expression is defined by IHC/ICC intensity score 1+, 2+, 3+  
LOX expression in biopsy and resection specimens is 
associated with extent of invasion 
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Invasive subtype 
mean LOX IHC score
*The H-index is a 
composite of % positive 
tumor cells per slide and 
the dominant intensity 
pattern of staining. 
Hirsch, J Clin Oncol, 2003 
Needle biopsy immunostaining correlates with tissue immunostaining. 
Spearman’s correlation for LOX ICC and LOX IHC, rs= 0.50, p= 0.036. 
Spearman’s rank correlation of LOX expression in 
biopsy and resection specimens 
rs = 0.5, p = 0.036 
LOXL2 expression in resected adenocarcinoma is 
increased in the progression from AIS to LPA 
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Invasive subtype 
mean LOXL2 IHC score
There is no correlation between LOXL2 ICC and LOXL2 IHC. 
Spearman’s rank correlation of LOXL2 expression in 
biopsy and resection specimens 
rs = 0.39, p = 0.11 
LOX and LOXL2 conclusions 
• These data confirm the association between 
adenocarcinoma invasive subtype and LOX and LOXL2 
expression in lung adenocarcinoma. 
 
• Cellular expression of LOX in pre-resection biopsy 
specimens is associated with lung adenocarcinoma 
invasiveness. 
 
• Prospective validation of tumor biopsy LOX expression 
patterns in larger sample sets could lead to development of 
new lung cancer biomarkers. When confirmed, these data 
suggest a role for LOX immunostaining as a biomarker to 
predict tumor aggressiveness.  
The tumor microenvironment modulates invasion and 
metastasis 
LPA 
 
AIS 
 
LPA+AIS 
 
Joyce, Nature Rev Cancer, 2009; Powell, unpublished data 
Thrombospondin-2 (TSP-2) is a stromal marker of 
invasion and poor prognosis 
• TSP-2 is overexpressed in the stroma of human and murine 
invasive lung adenocarcinoma. 
 
• Treatment of SKLU-1 cells with exogenous recombinant TSP-2 
had no effect on cell proliferation but increased invasion 
through Matrigel membrane by 2.5-fold. 
Powell, unpublished data 
37 genes 
106 genes 
LPA dominant AIS dominant 
RNA Sequencing of invasive and noninvasive lung 
adenocarcinoma specimens reveals 143 differentially 
expressed genes 
• Supervised clustering of 
differentially expressed 
genes for 12 LPA and 21 AIS 
lung adenocarcinoma 
specimens. 
 
• Class comparison between 
invasive (LPA) and 
noninvasive (AIS) genes was 
restricted to a significance 
threshold p <0.01 and those 
genes with >1.5-fold 
difference in expression. 
Yoo, Zhu, unpublished data 
Clinical implications 
• Biomarkers of invasion in lung adenocarcinoma, such as LOX and 
LOXL2, MDM2 and CDK4, and TSP-2 may be important mediators of 
tumor invasion and metastasis. 
 
• High-throughput approaches such as RNA Sequencing will bring forth 
new targets for prospective validation in larger sample sets. 
 
• Early prediction of tumor invasion and aggressiveness can stratify 
risk and guide clinical decision-making regarding optimal therapy 
for small, early-stage lung cancers. 
Early Stage Lung Cancer: 
FNA as a diagnostic tool 
What is an acceptable rate of non-malignant 
diagnoses in lung cancer resection surgery? 
 
• Principle: 
• Minimize risks in resecting non-malignant lesions. 
• Maximize resection of all lung cancers that require resection. 
Gould, Chest, 2013 
What is the role of FNA in the diagnosis of early 
stage (screen-detected) suspected lung cancer? 
What is the role of FNA in the diagnosis of early 
stage (screen-detected) suspected lung cancer? 
Mazzone, Chest, 2014 
FNA utility and accuracy 
• CT-guided FNA obtains a 
cytologic aspirate for: 
• H&E staining for cellular 
morphology 
• Immunohistochemistry for 
histologic subtyping 
• Cell block preservation for 
molecular analysis 
 
Schreiber, Chest, 2003; Travis, J Thoracic Onc, 2011  
• A pooled analysis of 24 studies of CT-guided 
transthoracic needle aspiration revealed: 
• Sensitivity of 0.92 (95% CI, 0.9-0.94) 
• Specificity of 0.97 (95% CI, 0.96-0.98) 
Hypothesis 
• Pre-operative FNA performed in a high-volume lung cancer 
center will decrease the rate of surgical resection for non-
malignant disease. 
 
• Objective:  To retrospectively examine the non-malignant 
resection rate (NMRR) and determine concordance of FNA 
results and surgical resection pathology. 
Methodology 
• Consecutive thoracic operations performed by the Mount Sinai 
Department of Thoracic Surgery during the 6-month period between 
February 1, 2014 and August 1, 2014 for known or suspected first 
primary lung cancer presenting with a lung nodule or mass. 
 
• Not included: 
• Patients with metastatic disease 
• Patients with prior lung cancer 
• Patients who received neoadjuvant chemotherapy prior to surgical resection 
 
• Data extracted from EMR: 
• Patient demographics 
• Smoking history 
• Nodule characteristics 
• Thoracic operation data 
 
Characteristics of entire cohort 
Patient demographics (n=119) 
Age, mean ± SD, y 66.1 ± 11.2 
Female, n 81 (64%) 
BMI, mean ± SD 26.6 ± 5 
Smoking history 
Never smoker, n 37 (29%) 
Current smoker, n 20 (16%) 
Former smoker, n 70 (55%) 
Years smoked*,  
mean ± SD, y 
34 ± 16.3 
COPD or emphysema, n 54 (43%) 
Personal history of 
cancer, n 
39 (31%)  
Nodule and operative characteristics (n=127) 
Nodule size, mean ± SD, 
mm 
20.9 ± 11.7 
PET scan performed, n 104 (82%) 
PET SUVmax#, mean ± SD 4.3 ± 3.4 
Thoracic operation 
VATS, n 94 (74%) 
Thoracotomy, n 33 (26%) 
Extent of resection 
Sublobar, n 74 (58%) 
Lobectomy, n 53 (42%) 
*Smoking history available for 120 of 127 current or formerly smoking subjects, with range 3-70 years 
#SUVmax unavailable for 11 of 105 subjects who underwent PET 
Characteristics of entire cohort 
Cytology and pathology results N (%) 
Pre-operative core biopsy 9 (7%) 
FNA or core biopsy categorization (n=78, 61%) 
No pre-operative FNA performed 49 (39%) 
Malignant 62 (49%)  
Suspicious 8 (6%) 
Atypical 3 (2%) 
Nondiagnostic 2 (1%) 
Benign 3 (2%) 
Resection pathology 
Primary lung neoplasm 107 (84%) 
Non-malignant disease 20 (16%) 
*PET avidity defined as SUVmax >2 
Preliminary results 
• 127 surgical resections from 119 patients among 10 
cardiothoracic surgeons 
 
• Overall non-malignant resection rate 
 (NMRR) = 20/127 (15.7%) 
• Among 10 surgeons, the non-malignant resection rate varied 
from 6.5% to 36%. 
 
NMRR is decreased in patients with a pre-operative 
diagnostic FNA 
127 
resections 
78 nodules 
with pre-op 
FNA 
49 nodules 
without 
pre-op FNA 
8 nodules 
(10.3%) with 
non-
malignant 
pathology 
12 nodules 
(24.5%) with 
non-
malignant 
pathology 
Resection pathology 
Malignant 
(107) 
Non-malignant 
(20) 
Malignant 
(107) 
Non-
malignant 
(20) 
Pre-operative 
diagnostic 
testing 
FNA/ Core 
Positive* (70) 
69 1 
PET+# 41 0 
PET- 23 1 
No PET 5 0 
FNA 
Atypical (3) 
1 2 
PET+ 0 1 
PET- 0 1 
No PET 1 0 
FNA/ Core 
Benign (3) 
0 3 
PET+ 0 3 
PET- 0 0 
FNA/ Core 
Nondiagnostic 
(2) 
0 2 
PET+ 0 0 
PET- 0 1 
No PET 0 1 
FNA 
Not done (49) 
37 12 
PET+ 20 4 
PET- 8 1 
No PET 9 7 
*FNA positive includes Malignant and Suspicious categorizations. 
#PET+ defined by SUVmax >2; PET- by SUVmax ≤2. 
A positive FNA result more accurately predicts 
resection pathology compared with PET 
127 resections 
107 lung neoplasm 
70 nodules with 
pre-op FNA 
69 FNA+ 
(99%) 
92 nodules with 
pre-op PET 
61 PET+     
(SUVmax >2) 
(66%) 
20 non-malignant 
pathology 
8 nodules with  
pre-op FNA 
1 FNA+ 
12 nodules with 
pre-op PET 
8 PET+ 
Characteristics of patients with non-malignant 
pathology on resection 
Patient demographics (n=20) 
Age, mean ± SD, y 58.2 ± 11.6 
Female, n 10 (50%) 
BMI, mean ± SD 27.8 ± 5.6 
Smoking history 
Never smoker, n 13 (65%) 
Current smoker, n 1 (5%) 
Former smoker, n 6 (30%) 
Years smoked*, mean 
± SD, y 
21.5 ± 7.4 
COPD or Emphysema, n 5 (25%) 
Personal history of 
cancer, n 
7 (35%) 
Nodule and operative characteristics (n=20) 
Nodule size, mean ± SD, 
mm 
15.7 ± 8 
PET scan performed, n 12 (60%) 
PET SUVmax#, mean ± 
SD 
3.1 ± 1.5 
Thoracic operation 
VATS, n 17  (85%) 
Thoracotomy, n 3 (15%) 
Extent of resection 
Wedge resection, n 18 (90%) 
Lobectomy, n 2 (10%) 
*Smoking history available for 4 of 7 current or formerly smoking subjects, with range 5-43 years 
#SUVmax available for 11 of 12 subjects who underwent PET, with range 1.4-6. 
Cytology and pathology results, n N (%) 
Pre-operative core biopsy (nondx or benign) 2 (10%) 
FNA categorization 
No pre-operative FNA performed 12 (60%) 
Malignant 1 (5%) 
Suspicious 0 (0%) 
Atypical 2 (10%) 
Nondiagnostic 1 (5%) 
Benign 2 (10%) 
Resection pathology 
Granulomatous disease 12 (60%)  
Other 6 (25%) 
Organizing pneumonia 2 (10%) 
Intra-parenchymal lymph node 1 (5%) 
Interstitial/ peribronchial inflammation 1 (5%) 
Lymphoplasmacytic infiltrates 1 (5%) 
Apical cap 1 (5%) 
Benign tumors (hamartoma, inflammatory myofibroblastic tumor) 2 (10%) 
*PET avidity defined as SUVmax >2; PET status unknown for 3 patients. 
FNA Conclusions 
• Practice patterns vary widely among cardiothoracic surgeons 
within a single lung cancer center. 
 
• Non-malignant resection rate is lower in patients who have a 
pre-operative FNA, compared with those who do not. 
 
• FNA more accurately predicts resection pathology compared 
with PET among patients who undergo resection for a lung 
neoplasm. 
• FNA can provide a definitive diagnosis and allows for further molecular 
studies to be performed on biopsy specimens. 
Future directions 
Additional tumor biology questions 
• What are additional pathways important in acquisition of 
tumor invasiveness and metastasis, and can targeted therapies 
effectively halt tumor growth and invasion? 
 
• Targets for immune activation and checkpoint inhibition (anti-
PD1 and anti-PDL1 antibodies). 
 
• These and other biomarkers can be investigated in neoadjuvant 
window of opportunity clinical trials of targeted therapeutics. 
Additional clinical questions 
• How should screen-detected non-solid lung nodules be 
managed? 
• How quickly do they grow? Can they be observed? 
• Should sub-solid nodules be resected once a solid component develops? 
• Do biomarkers of invasiveness predict outcome and guide clinical 
decision making? 
 
• What is the role of limited surgical resection? 
• Do wedge resection and segmentectomy have similar outcomes when 
compared with lobectomy? 
• Which nodules (size, location, density) are most amenable to sub-lobar 
resection? 
Summary points 
• Pathways for lung cancer metastasis and invasion provide potential 
targets for therapy and biomarkers by which to guide prognostication 
and clinical decision-making. 
 
• Clinical workup of nodules suspicious for lung cancer requires further 
investigation to determine the most accurate diagnostic modalities 
based upon a priori risk. 
 
• Lung cancer screening for high-risk current and former smokers will 
further highlight these controversies through a sharp increase in the 
number of early stage lung cancers. Tools that allow us to distinguish 
indolent from aggressive tumors will maximize benefit and reduce 
harms from lung cancer screening. 
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